Zimmer Biomet (NYSE:ZBH) Issues FY 2026 Earnings Guidance

Zimmer Biomet (NYSE:ZBH) updated its FY 2026 earnings guidance on Tuesday. The company provided EPS guidance of 8.400-8.550 for the period, compared to the consensus EPS estimate of 8.390. The company issued revenue guidance of $8.4 billion-$8.6 billion, compared to the consensus revenue estimate of $8.5 billion.

Analyst Ratings Changes

Several equities analysts recently commented on the company. Needham & Company LLC restated a “hold” rating on shares of Zimmer Biomet in a research report on Tuesday, February 10th. UBS Group restated a “sell” rating and set a $89.00 target price on shares of Zimmer Biomet in a research report on Wednesday, February 11th. Citizens Jmp dropped their target price on Zimmer Biomet from $120.00 to $105.00 and set a “market outperform” rating for the company in a research report on Wednesday. Wells Fargo & Company dropped their target price on Zimmer Biomet from $98.00 to $90.00 and set an “equal weight” rating for the company in a research report on Wednesday. Finally, William Blair started coverage on Zimmer Biomet in a research report on Friday, February 20th. They set a “market perform” rating for the company. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, thirteen have given a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $102.43.

Zimmer Biomet Trading Up 2.3%

NYSE:ZBH traded up $1.82 on Thursday, reaching $81.89. The company’s stock had a trading volume of 978,392 shares, compared to its average volume of 2,279,938. Zimmer Biomet has a 1-year low of $79.83 and a 1-year high of $108.29. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.10 and a current ratio of 1.98. The firm has a market cap of $15.85 billion, a PE ratio of 23.15, a PEG ratio of 1.89 and a beta of 0.61. The business’s 50-day moving average price is $92.87 and its two-hundred day moving average price is $92.81.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings data on Tuesday, April 28th. The medical equipment provider reported $2.09 earnings per share for the quarter, topping the consensus estimate of $1.86 by $0.23. The company had revenue of $2.09 billion during the quarter, compared to analysts’ expectations of $2.06 billion. Zimmer Biomet had a return on equity of 12.93% and a net margin of 8.56%.Zimmer Biomet’s revenue for the quarter was up 9.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.81 earnings per share. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. Equities research analysts anticipate that Zimmer Biomet will post 8.39 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, April 30th. Investors of record on Tuesday, March 31st will be given a dividend of $0.24 per share. The ex-dividend date of this dividend is Tuesday, March 31st. This represents a $0.96 annualized dividend and a yield of 1.2%. Zimmer Biomet’s dividend payout ratio is 27.12%.

Insider Activity

In other news, SVP Lori Winkler sold 2,650 shares of the firm’s stock in a transaction that occurred on Thursday, March 12th. The stock was sold at an average price of $94.66, for a total value of $250,849.00. Following the completion of the sale, the senior vice president directly owned 10,224 shares of the company’s stock, valued at $967,803.84. This trade represents a 20.58% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. 1.28% of the stock is currently owned by insiders.

Key Zimmer Biomet News

Here are the key news stories impacting Zimmer Biomet this week:

• Positive Sentiment: Q1 beat and raised guidance — Zimmer Biomet reported Q1 EPS of $2.09 (vs. $1.86 est.) and revenue of about $2.09B, with revenue up ~9% year/year and the firm raising FY 2026 EPS guidance to roughly $8.40–8.55. This underpins the company’s underlying operational strength. Earnings Call Highlights
• Neutral Sentiment: Full call/transcript and coverage — The earnings call and full transcripts are available (useful for details on segment performance and margin drivers). Market commentary notes the beats but some premarket/early weakness after results. Earnings Call Transcript
• Neutral Sentiment: Stock “buzz” and peer performance — Data vendors flagged rising buzz across NYSE composites but MarketWatch noted ZBH underperformed peers on the day; these are informational signals rather than direct fundamentals. Buzz Grows Across NYSE Composite Trend
• Negative Sentiment: Finance chief resignation — A senior finance executive departure prompted a large intraday decline and headlines describing a plunge to a multi?year low, creating near?term uncertainty around financial leadership and execution. Plunges to 13-Year Low on Finance Chief Resignation
• Negative Sentiment: Analyst price?target cuts and rating shifts — Multiple firms trimmed targets or issued neutral/equal?weight opinions (JPMorgan to $95/neutral; Wells Fargo to $90/equal weight; Truist trimmed target to $92 while keeping hold). The cluster of cuts is weighing on sentiment and likely amplifying the sell?off. Analyst Actions (Benzinga)

Hedge Funds Weigh In On Zimmer Biomet

Hedge funds and other institutional investors have recently modified their holdings of the business. AQR Capital Management LLC lifted its holdings in Zimmer Biomet by 276.6% during the 2nd quarter. AQR Capital Management LLC now owns 1,300,593 shares of the medical equipment provider’s stock worth $118,627,000 after buying an additional 955,284 shares during the period. Victory Capital Management Inc. lifted its holdings in Zimmer Biomet by 28.6% during the 4th quarter. Victory Capital Management Inc. now owns 2,475,768 shares of the medical equipment provider’s stock worth $223,529,000 after buying an additional 551,005 shares during the period. Schonfeld Strategic Advisors LLC lifted its stake in shares of Zimmer Biomet by 3,633.7% in the 3rd quarter. Schonfeld Strategic Advisors LLC now owns 464,250 shares of the medical equipment provider’s stock valued at $45,729,000 after purchasing an additional 451,816 shares during the period. The Manufacturers Life Insurance Company increased its position in Zimmer Biomet by 30.5% in the 4th quarter. The Manufacturers Life Insurance Company now owns 1,544,646 shares of the medical equipment provider’s stock valued at $139,054,000 after buying an additional 360,624 shares in the last quarter. Finally, Invesco Ltd. increased its position in Zimmer Biomet by 10.6% in the 4th quarter. Invesco Ltd. now owns 3,361,075 shares of the medical equipment provider’s stock valued at $302,228,000 after buying an additional 322,689 shares in the last quarter. Institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.